Eversept Partners
Eversept Partners reported 107 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (10.1%), EHC (7.6%) and ENSG (7.2%). Compared with Q2 2026, the fund opened new positions in GH, WAT and GRAL, added to UTHR, EHC and ENSG, trimmed NTRA, SNDX and CLDX and sold out of GSK, LLY and AMN.
Latest filing: what Eversept Partners did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() UTHR United Therapeutics Corp Del | $176M | 10.1% | 325K | +37K (+13%) | 8 of 8 | |
| 2 | ![]() EHC Encompass Health Corp | $131M | 7.6% | 1.1M | +55K (+5%) | 4 of 8 | |
| 3 | ![]() ENSG Ensign Group Inc | $125M | 7.2% | 726K | +124K (+21%) | 3 of 8 | |
| 4 | ![]() ABVX Abivax SA | $109M | 6.3% | 1.1M | +187K (+20%) | 5 of 8 | |
| 5 | ![]() VERA Vera Therapeutics Inc | $76.3M | 4.4% | 2.4M | +149K (+7%) | 8 of 8 | |
| 6 | ![]() RVTY Revvity Inc | $68.8M | 4.0% | 450K | +366K (+438%) | 8 of 8 | |
| 7 | ![]() NTRA Natera Inc | $53M | 3.0% | 128K | −48K (−27%) | 8 of 8 | |
| 8 | ![]() CTRE Caretrust REIT Inc | $49.5M | 2.9% | 1.4M | +281K (+26%) | 2 of 8 | |
| 9 | ![]() OHI Omega Healthcare Invs Inc | $46.7M | 2.7% | 1M | +525K (+109%) | 3 of 8 | |
| 10 | ![]() SNDX Syndax Pharmaceuticals Inc | $45.9M | 2.6% | 2.4M | −355K (−13%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() GSK Gsk PLC ADR F | $25.3M | 482K |
![]() LLY Eli Lilly & Co | $24.1M | 20K |
![]() AMN Amn Healthcare Svcs Inc | $13.9M | 429K |
![]() CELC Celcuity Inc | $13.4M | 128K |
![]() HUM Humana Inc | $12.4M | 31K |
🔒 Free account: see all 30.
Options
valued at the underlying sharesReported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Eversept Partners 13F FAQ
What does Eversept Partners own?
Eversept Partners reported 107 stocks worth $1.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (10.1%), EHC (7.6%) and ENSG (7.2%). The table above lists every position in the filing (the top 10 without an account).
What did Eversept Partners buy and sell in Q3 2026?
Compared with Q2 2026: 22 new positions, 31 added to, 47 trimmed and 30 sold out. New positions include GH, WAT and GRAL. It sold all of GSK, LLY and AMN.
When will Eversept Partners file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Eversept Partners's portfolio worth?
The Q3 2026 filing reports $1.7B in US stocks ($1.9B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.



























